Biotech

All Articles

Regeneron's Opdualag opponent shows 57% response fee

.Regeneron is back along with lasting consequence for its own LAG-3 prevention and also PD-1 inhibit...

AstraZeneca articles records on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early look at the performance of its in-house antibody-drug conjugate (AD...

iTeos- GSK's TIGIT celebrity reveals significant renovation

.After introducing a stage 3 launch based upon beneficial midstage outcomes, iTeos and also GSK are ...

More collaborative FDA may speed up unusual illness R&ampD: record

.The FDA needs to be much more open as well as collective to discharge a surge in approvals of unusu...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It's an extraordinarily hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bi...

Atea's COVID antiviral fails to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually fallen short another COVID-19 test, however the biotec...

Neurocrine's offer to conserve schizophrenia prospect stops working

.Neurocrine Biosciences' schizophrenia plan pivot has actually fallen short. The biotech was actuall...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue entry to the radioligand party, paying out 100 million europeans ($ 110 ...

F 2G increases $100M for second effort to acquire new antifungal to market

.After F2G's 1st effort to get a brand-new lesson of antifungal to market was derailed by the FDA, t...

Moderna targets $1.1 B in R&ampD investing cuts, drops 5 plans in the middle of profits tensions

.Moderna has vowed to cut R&ampD spending by $1.1 billion by 2027. The decision to retract the budge...